Protective efficacy of recombinant Modified Vaccinia virus Ankara (MVA) delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein
Journal of virology | 29 May 2015
A Volz, A Kupke, F Song, S Jany, R Fux, H Shams-Eldin, J Schmidt, C Becker, M Eickmann, S Becker and G Sutter
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant MVA vaccine expressing full-length MERS-CoV spike glycoprotein (S) by immunizing BALB/c mice using either intramuscular or subcutaneous regimens. In all cases MVA-MERS-S induced MERS-CoV-specific CD8+ T-cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.
* Data courtesy of Altmetric.com